Skip to main content
      Watch: Another TYK2 Ticks the Boxes

      Dr. Janet Pope discusses late-breaking abstract L12 presented at #ACR23.

      https://

      Dr. John Cush RheumNow

      1 year ago
      Watch: Another TYK2 Ticks the Boxes Dr. Janet Pope discusses late-breaking abstract L12 presented at #ACR23. https://t.co/1SGuIFOWt6 https://t.co/tb4LRbmfiI
      We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but there has been relatively little to say about how to treat it. To date there have been over twice as many publications about VEXAS (263 publications) as there have been patients described with respect to treatment strategies (116 patients). One of the late breaking abstracts may finally have rectified this imbalance.
      Should rheumatologists be counseling patients on cervical cancer prevention and screening? The data from Abstract #1479 at ACR Convergence 2023 suggests that this should be an important conversation with our female lupus patients.
      #ACR23 – Day 1 Report

      The day began with a bang with the Year in Review that featured the sage insights of Drs. Phil

      Dr. John Cush RheumNow

      1 year ago
      #ACR23 – Day 1 Report The day began with a bang with the Year in Review that featured the sage insights of Drs. Philip Seo and Tomas Mustelin about the scientific and clinical rheumatology highlights from the past year. https://t.co/a79M2boHRH https://t.co/5P18ybazGK
      Taylor et al. Novel blood assay for sero+ and sero- RA. Differentiates well from other diseases. May be very valuable fo

      Richard Conway

      1 year ago
      Taylor et al. Novel blood assay for sero+ and sero- RA. Differentiates well from other diseases. May be very valuable for sero- RA diagnosis = sensitivity 83.7%, +LR 21.46, and -LR 0.17. Needs validation. Abstr#2586 #ACR23 @RheumNow https://t.co/jw41F8YohE https://t.co/kXi3km0b07
      Last abstract of #ACR23 was #ACRBest

      Plasma cfDNA signatures (synovial mapped) to identify RA vs OA, other inflamm arth

      David Liew drdavidliew

      1 year ago
      Last abstract of #ACR23 was #ACRBest Plasma cfDNA signatures (synovial mapped) to identify RA vs OA, other inflamm arthritis Great performance, even with seroneg RA A blood test to: diagnose ?phenotype ?identify best b/tsDMARD Could be massive Peter Taylor ABST2586 @RheumNow https://t.co/tJX2jXV0Oe
      #ACRbest Yrin Preview @ACRheum
      J Bathon

      Take home
      Symptomatic #Rx of ACPA+ people WITH #DMARD is too late to alter risk

      Janet Pope

      1 year ago
      #ACRbest Yrin Preview @ACRheum J Bathon Take home Symptomatic #Rx of ACPA+ people WITH #DMARD is too late to alter risk of #RA when drug is d/c AI to read joint erosions on X-ray May be ‘too little too late’ #Steroids in #RA increase #MACE even after d/c #ACR23 @RheumNow
      Identifying GCA diagnosis and disease activity through proteomics from plasma:
      diagnosis looks good
      disease activity loo

      David Liew drdavidliew

      1 year ago
      Identifying GCA diagnosis and disease activity through proteomics from plasma: diagnosis looks good disease activity looks harder (Much like a lot of things in GCA, really) Exciting work @MayoClinic @MdWarrington @jsung0906 #ACR23 ABST2601 @RheumNow https://t.co/SwxN58LieB
      #ACR23 Yr in Preview
      J Bathon
      Shared decision making w tradeoffs showed sex differences for concerns & preferences

      Janet Pope

      1 year ago
      #ACR23 Yr in Preview J Bathon Shared decision making w tradeoffs showed sex differences for concerns & preferences in #RA present dependent on how you ask the questions Unmet needs (I think 🤔) biomarkers of flare for #inflammatory #arthritis Rx select’n/retention @RheumNow
      Watch: Assessment and Treatment of Cardiovascular Risks in Rheumatoid Arthritis

      Dr. Antoni Chan discusses abstract 038

      Dr. John Cush RheumNow

      1 year ago
      Watch: Assessment and Treatment of Cardiovascular Risks in Rheumatoid Arthritis Dr. Antoni Chan discusses abstract 0387 and abstract 0391 presented at #ACR23 https://t.co/avnarOGZui https://t.co/4CeAumv31b
      Greigert et al. IL17 in GCA. Increases vascular inflammation. Synergistic effect on myofibroblasts with IFN-γ - increas

      Richard Conway

      1 year ago
      Greigert et al. IL17 in GCA. Increases vascular inflammation. Synergistic effect on myofibroblasts with IFN-γ - increases IL-1B, IL-6, GM-CSF, CCL20 (recruits T cells), CCL2 (recruits monocytes), VEGF (neoangiogenic). Abstr#2599 #ACR23 @RheumNow https://t.co/p4GumZStAZ https://t.co/zZv0TF4fmn
      Telitacicept a recombinant fusion protein targeting, neutralizing BLyS and APRIL, phase 3 study in RA MTX-IR at 24 wk, A

      Dr. Antoni Chan

      1 year ago
      Telitacicept a recombinant fusion protein targeting, neutralizing BLyS and APRIL, phase 3 study in RA MTX-IR at 24 wk, ACR20 (60% vs 27% PBO), ACR50 (21% vs 6% PBO), reduced DAS28-ESR, no radiographic progression, Wang L Abst#L20 #ACR23 #ACRBest @RheumNow https://t.co/nuvizqQZsR https://t.co/PRtlea3AqU
      #ACR23 Abstr#2587 Can we agree on how to measure frailty in #SLE? A cohort study: moderate agreement at best among SLICC

      Md Yuzaiful Md Yusof

      1 year ago
      #ACR23 Abstr#2587 Can we agree on how to measure frailty in #SLE? A cohort study: moderate agreement at best among SLICC-FI, SPPB, FRAIL=>2 & PROMIS PF=<40. SLICC-FI was robust predictor of all outcomes except for cognitive impairment. FRAIL & PROMIS not far behind @RheumNow https://t.co/qWjM4crPvg